ROBERT ZAPOTOSKY: Open Payments
NPI 1841648573 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$640 in 29 payments from 11 companies in 2025. Trend: 2023 $2,577 · 2024 $50 · 2025 $640
Food & beverage: $640
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $145 |
| Novartis Pharmaceuticals Corporation | 4 | $103 |
| Arcutis Biotherapeutics, Inc. | 4 | $102 |
| GENZYME CORPORATION | 2 | $86 |
| Incyte Corporation | 3 | $60 |
| Lilly USA, LLC | 1 | $33 |
| Janssen Biotech, Inc. | 2 | $33 |
| Amgen Inc. | 1 | $27 |
| UCB, Inc. | 1 | $21 |
| LNHC, Inc | 1 | $16 |
Products named: Zoryve, DUPIXENT, SKYRIZI, Rhapsido, RINVOQ, OPZELURA, TALTZ, TREMFYA.
Industry payments across CA — which companies pay providers there.
